Progesterone pills could boost mental health in transgender women
NCT ID NCT06807580
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether taking oral progesterone (200 mg daily) can reduce psychological distress in transgender women who have been on hormone therapy for at least 6 months. It also looks at effects on sleep, breast size, quality of life, and heart health. About 40 participants will receive either progesterone or a placebo for several weeks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Progesterone (oral micronized progesterone 200 mg)
- What this could lead to
- If it works, this could point toward a way to improve mental health, sleep, and breast development for transgender women on hormone therapy.
- What could go wrong
- This is a small early-phase trial with only 40 participants, so results may not apply to everyone. Progesterone can cause side effects like drowsiness or liver issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2025
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Male participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: \- Participants will be transgender women, who have been on gender-affirming hormone therapy for at least 6 months before the start of the study. Exclusion Criteria: * Peanut allergy * Liver disease (liver enzyme elevations and/or evidence of acute or chronic hepatitis). In our lab, the upper limit of normal for aspartate aminotransferase (AST) is 39, and the upper limit of normal for alanine aminotransferase (ALT) is 52. * Stage 4/5 chronic kidney disease * Congestive heart failure * Medical disease or medication use associated with gynecomastia (i.e tumor, hyperthyroidism, chronic kidney disease, cirrhosis, ACE inhibitors, statins, haloperidol, tricyclic antidepressants, atypical antipsychotics) * Pre-existing cardiovascular disease * Prior or current history of thromboembolism, known clotting disorders, current or recent anti-thrombotic therapy for venous thromboembolism. * History of breast cancer * Prior progesterone use * Uncontrolled depression and/or suicidal ideation * Current hypothyroidism (even if controlled with treatment) Progesterone in Gender Affirming Hormone Therapy 9 Version #4, 10/30/24 * Cannabis use of greater than 1 use/week in the past 3 months * Previously identified BRCA 1 or 2 gene mutation or other familial breast cancer. * Abnormal mammogram (if indicated - for patients above the age of 50 and on estrogen for 5 or more years OR positive family history of breast cancer) with results of BIRADS 3 or higher. Subjects with a BIRADS 0 mammogram must have undergone additional imaging demonstrating BIRADS 1 or 2 prior to enrollment. * Have had or are planning to undergo breast enhancement or gender affirming top surgery in the next 6 months * Uncontrolled hypertension, defined as systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mmHg. * Triglycerides ≥ 500 mg/dL. * In our lab, the upper limit of normal for aspartate aminotransferase (AST) is 39, and the upper limit of normal for alanine aminotransferase (ALT) is 52. * Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73m2. * Estradiol levels outside the stable range (100-300 pg/mL) * Heavy smoking, defined as 25+ cigarettes per day * Non-English speaking or those with limited English proficiency
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Transgender women are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Emory Transgender Clinic
RECRUITINGAtlanta, Georgia, 30308, United States